Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News IGM Biosciences Inc IGMS

Healthcare Biotechnology
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites.... see more

Recent & Breaking News (NDAQ:IGMS)

IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference

GlobeNewswire December 1, 2022

IGM Biosciences to Present at Three Upcoming Investor Conferences

GlobeNewswire November 8, 2022

IGM Biosciences Announces Third Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire November 3, 2022

IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma

GlobeNewswire November 2, 2022

IGM Biosciences to Present at Three Upcoming Investor Conferences

GlobeNewswire September 6, 2022

IGM Biosciences Announces Second Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire August 8, 2022

IGM Biosciences to Present at the 2022 Jefferies Healthcare Conference

GlobeNewswire June 1, 2022

IGM Biosciences to Present at the 2022 RBC Capital Markets Global Healthcare Conference

GlobeNewswire May 10, 2022

IGM Biosciences Announces First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 9, 2022

IGM Biosciences Announces Closing of Global Collaboration Agreement with Sanofi

GlobeNewswire May 6, 2022

IGM Announces Closing of $230.0 Million Public Offering

GlobeNewswire April 6, 2022

IGM Announces Pricing of $200.0 Million Public Offering

GlobeNewswire March 30, 2022

IGM Announces Proposed Public Offering

GlobeNewswire March 29, 2022

IGM Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 29, 2022

IGM Biosciences to Host Conference Call and Webcast Today to Discuss Global Collaboration Agreement with Sanofi

GlobeNewswire March 29, 2022

IGM Biosciences Advances Novel Antibody IGM-6268 Into Clinical Trials for the Treatment and Prevention of COVID-19

GlobeNewswire February 9, 2022

IGM Biosciences to Present at the Guggenheim 2022 Oncology Conference

GlobeNewswire February 3, 2022

IGM Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2022

IGM Biosciences Presents Clinical Data from IGM-2323 in Patients with Advanced B Cell Malignancies at 2021 American Society of Hematology Annual Meeting

GlobeNewswire December 11, 2021

IGM Biosciences to Collaborate on the Study of IgM and IgA Antibodies for the Prevention of Malaria

GlobeNewswire December 8, 2021